Tagged with P

Portugal Dr Maria Mota, executive director at Portugal’s Institute of Molecular Medicine (iMM), shares how the non-profit institute generated its own circular economy during the COVID-19 pandemic and saved the Portuguese government some EUR 15 million thanks to its in-house developed PCR tests. She describes the expanson of the iMM’s focus…

Portugal Pedro Moura, managing director at Merck Portugal, outlines the company’s unique presence and the Portuguese affiliate’s diverse portolio. He discusses the challenges around access to innovation in Portugal, where only 44 percent of the drugs approved in the European Union make it to the local market and time to reimbursement…

Portugal The top 10 pharma companies in Portugal ranked by sales value in both the hospital and pharmacy markets. These charts are from IQVIA and are based on a moving annual total up to October 2023. Household Big Pharma names like Janssen (recently rebranded as Johnson & Johnson Innovative Medicines), Roche,…

Portugal Country manager at Lundbeck Portugal, Sara Barros, came to the Danish company after a number of management positions at larger pharma companies and took on the leadership of its local affiliate about three years ago. She comments on the shift in societal attitudes towards mental health, discusses Portugal’s psychiatric care…

Portugal President of the Portuguese Association Against Leukaemia (APCL), Dr Manuel Abecasis is known as the father of bone marrow transplants in Portugal. He outlines the APCL’s activities, including the organisation’s role in raising awareness and increasing the number of donars in the Portuguese Bone Marrow Donor Registry, which went from…

Denmark After transitioning from a fledgling biotech to a mature commercial-stage company on the back of its first approval, Zealand Pharma was hit with the challenges of commercialisation and the disappointing sales of its severe hypoglycemia treatment, Zegalogue. As a result, in 2022, the Danish firm did an about face, sacked…

China The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact Therapeutics cancer drug deal; new Changchun GeneScience Pharmaceutical R&D centre in Shanghai, and MGI Tech’s bet on Australia.   AstraZeneca,…

USA Drawing on her experience as rare disease patient advocacy group SYNGAP1 Foundation’s founder and former president, Monica Weldon argues for the need to standardize genomic testing practices, warns against the possible ethical implications of individualized medicine, and makes a cause for a more holistic approach within rare disease communities.  …

France Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the sixth health minister since 2017, is not expected to stay long after accusations relating to gifts she obtained from pharma…

India KV Subramaniam, president of Reliance Life Sciences, a research-driven medical biotech with a fully integrated value chain that covers everything from research to manufacturing, comments on the firm’s unique positioning and its efforts to diversify its portfolio. Moving beyond plasma proteins and biosimilars, Reliance looks to expand into vaccines and…

India Suresh Pattathil wears two hats within India’s vast pharma ecosystem. Not only is he responsible for managing AbbVie India as its Managing Director and GM, he also advocates for broader pharma interests as president of the Organization of Pharmaceutical Producers of India (OPPI). He speaks about India’s goal of fostering…

Portugal Speaking to PharmaBoardroom as Janseen is rebranding as Johnson & Johnson Innovative Medicine, managing director for Portugal, Filipa Mota e Costa, discusses the affiliate’s expanded local footprint and its ranking as the number one pharmaceutical company in the country. She also explains Portugal’s market access progress, including the consolidation of…